TY - JOUR
T1 - Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition
AU - Tsilidis, Konstantinos K.
AU - Allen, Naomi E.
AU - Key, Timothy J.
AU - Sanjoaquin, Miguel A.
AU - Bakken, Kjersti
AU - Berrino, Franco
AU - Fournier, Agnès
AU - Lund, Eiliv
AU - Overvad, Kim
AU - Olsen, Anja
AU - Tjønneland, Anne
AU - Byrnes, Graham
AU - Chajes, Veronique
AU - Rinaldi, Sabina
AU - Boutron-Ruault, Marie Christine
AU - Clavel-Chapelon, Francoise
AU - Chang-Claude, Jenny
AU - Kaaks, Rudolf
AU - Bergmann, Manuela
AU - Boeing, Heiner
AU - Koumantaki, Yvoni
AU - Palli, Domenico
AU - Pala, Valeria
AU - Panico, Salvatore
AU - Tumino, Rosario
AU - Vineis, Paolo
AU - Bas Bueno-De-Mesquita, H.
AU - Van Gils, Carla H.
AU - Peeters, Petra H M
AU - Rodríguez, Laudina
AU - González, Carlos A.
AU - Sánchez, María José
AU - Chirlaque, Maria Dolores
AU - Barricarte, Aurelio
AU - Dorronsoro, Miren
AU - Khaw, Kay Tee
AU - Rodwell, Sheila A.
AU - Norat, Teresa
AU - Romaguera, Dora
AU - Riboli, Elio
PY - 2011/4/15
Y1 - 2011/4/15
N2 - Menopausal hormone therapy (HT) may influence colorectal cancer risk. A total of 136,275 postmenopausal women from the European Prospective Investigation into Cancer and Nutrition were followed for an average of 9 years, during which time 1,186 colorectal cancers were diagnosed. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox proportional hazards models stratified by center and age, and adjusted for body mass index, smoking, diabetes, physical activity and alcohol consumption. Compared to never use of HT at study enrolment, current use of estrogen-only (HR, 1.02; 95% CI, 0.79-1.31) or estrogen plus progestin (HR, 0.94; 95% CI, 0.77-1.14) was not significantly associated with the risk of colorectal cancer, and these associations did not vary by recency, duration, route of administration, regimen or specific constituent of HT. Our results show no significant association of estrogen-only or estrogen plus progestin therapy with colorectal cancer risk.
AB - Menopausal hormone therapy (HT) may influence colorectal cancer risk. A total of 136,275 postmenopausal women from the European Prospective Investigation into Cancer and Nutrition were followed for an average of 9 years, during which time 1,186 colorectal cancers were diagnosed. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox proportional hazards models stratified by center and age, and adjusted for body mass index, smoking, diabetes, physical activity and alcohol consumption. Compared to never use of HT at study enrolment, current use of estrogen-only (HR, 1.02; 95% CI, 0.79-1.31) or estrogen plus progestin (HR, 0.94; 95% CI, 0.77-1.14) was not significantly associated with the risk of colorectal cancer, and these associations did not vary by recency, duration, route of administration, regimen or specific constituent of HT. Our results show no significant association of estrogen-only or estrogen plus progestin therapy with colorectal cancer risk.
KW - cohort study
KW - colorectal cancer
KW - hormone replacement therapy
UR - http://www.scopus.com/inward/record.url?scp=79951994752&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951994752&partnerID=8YFLogxK
U2 - 10.1002/ijc.25504
DO - 10.1002/ijc.25504
M3 - Article
C2 - 20533550
AN - SCOPUS:79951994752
SN - 0020-7136
VL - 128
SP - 1881
EP - 1889
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 8
ER -